Related Experiment Video
Updated: Aug 7, 2026
12:03
In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
Published on: December 9, 2016
EF5 binding and clinical outcome in human soft tissue sarcomas
Sydney M Evans1, Douglas Fraker, Stephen M Hahn
1Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA. sydevans@mail.med.upenn.edu
International Journal of Radiation Oncology, Biology, Physics
|February 7, 2006
Summary
Hypoxia, measured by EF5 binding, correlates with metastasis in soft tissue sarcomas. This technique may help identify high-risk patients for early chemotherapy.
Area of Science:
- Oncology
- Medical Imaging
- Biochemistry
Background:
- Hypoxia is a critical factor in tumor progression and treatment resistance.
- Measuring tumor hypoxia can aid in patient stratification and treatment planning.
Purpose of the Study:
- To evaluate the 2-nitroimidazole agent EF5 as a hypoxia surrogate marker in soft tissue sarcomas.
- To determine if EF5-measured hypoxia correlates with patient outcomes.
Main Methods:
- Patients with soft tissue sarcomas received EF5 before surgery.
- Biopsy specimens were stained for EF5 binding and quantitatively analyzed.
- EF5 binding was correlated with prognostic factors and patient outcomes.
Main Results:
- EF5 binding correlated positively with histologic grade and mitoses in de novo tumors.
- High-grade and -stage de novo tumors showed higher EF5 binding.
- Moderate to severe hypoxia, high grade, or high mitoses were associated with increased metastasis risk.
Conclusions:
- EF5 binding shows promise for measuring hypoxia in soft tissue sarcomas.
- Further studies are needed to confirm EF5 as an independent prognostic factor.
- EF5 can help identify high-risk patients for clinical trials evaluating early chemotherapy.
